ロード中...
Y-site Incompatibility Between Premix Concentrations of Vancomycin and Piperacillin-Tazobactam: Do Current Compatibility Testing Methodologies Tell the Whole Story?
Background: Published literature has demonstrated commercially available premix vancomycin (5 mg/mL) and piperacillin-tazobactam (67.5 mg/mL) as physically compatible via simulated Y-site methodology. Compatibility via actual Y-site infusion has yet to be established. Objective: To assess and compar...
保存先:
| 出版年: | Hosp Pharm |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Thomas Land Publishers, Inc.
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5345911/ https://ncbi.nlm.nih.gov/pubmed/28321140 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1310/hpj5202-132 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|